Thursday 21 February 2019 ,
Thursday 21 February 2019 ,
Breaking News
  • Chawkbazar fire death toll rises to 69
  • Chawkbazar fire death toll rises to 69
5 February, 2018 00:00 00 AM

Cancer blood test ‘enormously exciting’

BBC News Health
Cancer blood test ‘enormously exciting’

James Gallagher

Scientists have taken a step towards one of the biggest goals in medicine - a universal blood test for cancer.

A team at Johns Hopkins University has trialled a method that detects eight common forms of the disease.

Their vision is an annual test designed to catch cancer early and save lives. UK experts said it was "enormously exciting".

However, one said more work was needed to assess the test's effectiveness at detecting early-stage cancers.

Tumours release tiny traces of their mutated DNA and proteins they make into the bloodstream.

The CancerSEEK test looks for mutations in 16 genes that regularly arise in cancer and eight proteins that are often released.

It was trialled on 1,005 patients with cancers in the ovary, liver, stomach, pancreas, oesophagus, colon, lung or breast that had not yet spread to other tissues.

Overall, the test found 70% of the cancers.

Dr Cristian Tomasetti, from Johns Hopkins University School of Medicine, told the BBC: "This field of early detection is critical.

"I think this can have an enormous impact on cancer mortality."

The earlier a cancer is found, the greater the chance of being able to treat it.

Five of the eight cancers investigated have no screening programmes for early detection.

In some cases, the test also provided information about the tissue-of-origin of the cancer - but not all.

Pancreatic cancer has so few symptoms and is detected so late that four in five patients die in the year they are diagnosed.

Finding tumours when they could still be surgically removed would be "a night and day difference" for survival, said Dr Tomasetti.

CancerSEEK is now being trialled in people who have not been diagnosed with cancer, which will be the real test of its usefulness.

The hope is it can complement other screening tools such as mammograms for breast cancer and colonoscopies for colorectal cancer.

Dr Tomasetti said: "We envision a blood test we could use once a year."

Universal test?

The CancerSEEK test, reported in the journal Science, is novel because it hunts for both the mutated DNA and the proteins.

Increasing the number of mutations and proteins being analysed would allow it to test for a wider range of cancers.

Dr Gert Attard, team leader in the Centre for Evolution and Cancer at the Institute of Cancer Research, London, and consultant medical oncologist at the Royal Marsden NHS Foundation Trust, told the BBC: "This is of massive potential.

 

"I'm enormously excited. This is the Holy Grail - a blood test to diagnose cancer without all the other procedures like scans or colonoscopy."

He said "we're very close" to using blood tests to screen for cancer as "we have the technology".

But he cautioned there was still uncertainty about what to do when a cancer was diagnosed.

In some cases, the treatment may be worse than living with a cancer that is not immediately life-threatening.

Men can already have slow growing prostate cancers closely monitored rather than treated.

"When we detect cancer in a different way, we can't take for granted that everyone will need treatment," Dr Attard said.

Early stage cancers

Prof Richard Marais, from Cancer Research UK, said it would take time to prove that it worked as an early diagnosis for cancer - at least five to six years.

"Detecting cancer early, before the disease has spread is one of the most powerful ways to improve cancer survival and this interesting research is a step towards being able to do this earlier than is currently possible."

Paul Pharoah, professor of cancer epidemiology at the University of Cambridge, said more work was needed to assess how the test performs when cancers are less advanced.

He said: "Demonstrating that a test can detect advanced cancers does not mean that the test will be useful in detecting early stage symptomatic cancer, much less pre-symptomatic cancer. The sensitivity for the stage 1 cancers in the study was only 40%."

And Dr Mangesh Thorat from the Centre for Cancer Prevention, Queen Mary University of London, said it looked promising "but with several caveats"

"A significant amount of further research is needed before we can even contemplate how this might play out in screening settings," he said.

"This is only a case-control study, and therefore needs further evaluation in large cohorts more representative of general population where such screening might be introduced."

The cost of CancerSEEK is less than $500 (£360) per patient, which is around the same price as a colonoscopy.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Our cover story this week is on Dental Disorders. Teeth are a very important part of the human body. They are the body's hardest and most durable…
Cancer’s long-term prognosis: As an oncologist I’ve never been so hopeful

Cancer’s long-term prognosis: As an oncologist I’ve never been so hopeful

“You’re an oncologist, isn’t that depressing?” Answering this question, posed with equal parts dread and fascination, is an occupational…
What are the most common dental problems?

What are the most common dental problems?

Tammy Davenport    Dental problems are never any fun, but the good news is that most of them can be easily prevented. Brushing twice a day,…
Tooth, cavities and root canal

Tooth, cavities and root canal

Our dental surgeons now a days talk about re-construction of a broken tooth with a chemical compound they call 'miracle mix' or magic mix'…
What can you do about sensitive teeth?

What can you do about sensitive teeth?

If you pass on hot or cold drinks because you know they’ll make your teeth hurt, it may be time to talk to your dentist about the possibility that…
Everything you need to know about bad breath

Everything you need to know about bad breath

Tim Newman Bad breath affects an estimated 25 percent of people. There are a number of possible causes of halitosis, but the vast majority come down to…
7 Daily ways to protect your teeth

7 Daily ways to protect your teeth

Some say the eyes are the window to the soul. But if you really want to know what someone’s about, check their smile. A welcoming show of pearly…
Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation

Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation

Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the…
Enhance social emotional learning along with cognitive capacity of the children with NDDs

Enhance social emotional learning along with cognitive capacity of the children with NDDs

Neurodevelopmental disorders (NDDs) are indicated by developmental deficits which usually appear at the early age of a child’s development and can…
icddr,b explores sustainable ways to improve WASH and menstrual hygiene management in RMG factories

icddr,b explores sustainable ways to improve WASH and menstrual hygiene management in RMG factories

icddr,b in partnership with The Waterloo Foundation, UK have undertaken a new study to explore water, sanitation and hygiene (collectively known as WASH)…
Researchers find clues that depression may speed brain aging

Researchers find clues that depression may speed brain aging

Memory and thinking skills naturally slow with age but now scientists are peeking inside living brains to tell if depression might worsen that decline—and…
FDA approves Spravato (esketamine) nasal spray for adults with treatment-resistant depression

FDA approves Spravato (esketamine) nasal spray for adults with treatment-resistant depression

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic…
FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

Mylan N.V. recently announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder,…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting